To further demonstrate the involvement of AP-1 pathway in SVT-induced lung cancer cell growth, we compared the combination treatment of SVT and AP-1 inhibitor (SR11302, 10 μM) with SVT or AP-1 inhibitor alone. This evidence concerns the gene FOSB and lung carcinoma.